ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087
15 déc. 2015 07h30 HE
|
ArQule, Inc.
Orphan drug designation marks significant regulatory milestone for phase 2 trialAdditional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations ...
ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib for Second-Line Hepatocellular Carcinoma
Planned interim analysis expected to occur early in the second quarter of 2016 BURLINGTON, Mass. and PARSIPPANY, N.J., Dec. 10, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) and Daiichi...
ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092
17 nov. 2015 07h30 HE
|
ArQule, Inc.
ArQule receives orphan drug designation for ARQ 092 in Proteus syndrome BURLINGTON, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) and the National Human Genome Research...
UPDATE -- ArQule Presents Data on Tivantinib and Proprietary Pipeline at AACR-NCI-EORTC Conference
09 nov. 2015 07h55 HE
|
ArQule, Inc.
Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
ArQule Presents Data on Tivantinib and Propietary Pipeline at AACR-NCI-EORTC Conference
09 nov. 2015 07h30 HE
|
ArQule, Inc.
Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
ArQule to Present Data on Tivantinib, ARQ 087, ARQ 092, and ARQ 751 at AACR-NCI-EORTC Conference
27 oct. 2015 07h30 HE
|
ArQule, Inc.
Single-agent and combination pre-clinical and clinical data supportive of on-going clinical trials BURLINGTON, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced...
ArQule to Report Third Quarter 2015 Financial Results on November 4, 2015
21 oct. 2015 07h30 HE
|
ArQule, Inc.
BURLINGTON, Mass., Oct. 21, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it will report financial results for the third quarter 2015 before the market opens on Wednesday,...
ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 and Next Generation AKT Inhibitor ARQ 751 in Oncology
15 oct. 2015 16h00 HE
|
ArQule, Inc.
Pre-Clinical Data Supports the Use of AKT1 and PI3K Mutations as Biomarkers for the Company’s AKT Inhibitors BURLINGTON, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today...
ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference
28 sept. 2015 07h30 HE
|
ArQule, Inc.
Preliminary Results of the Phase 1b Expansion Cohort Show Four Partial Responses in Targeted Patient Populations BURLINGTON, Mass., Sept. 28, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc....
ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study of Tivantinib in Hepatocellular Carcinoma at International Liver Cancer Association Conference
08 sept. 2015 07h30 HE
|
ArQule, Inc.
BURLINGTON, Mass., Sept. 08, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that additional analyses of plasma biomarkers support the prognostic and predictive role of MET...